Dirk Tomsitz

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Thomas U. Schulz, Sarah Zierold, Michael Sachse et al. · European Journal of Cancer · 2022 · 65 citations · Full text

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter et al. · The Lancet · 2023 · 63 citations

Tumor Immunology, Surgical Oncology, Nivolumab Versus Observation +10

Is drug allergy less prevalent than previously assumed? A 5-year analysis

Lucie Heinzerling, Dirk Tomsitz, M.D. Anliker · British Journal of Dermatology · 2011 · 42 citations

Cofactors of wheat-dependent exercise-induced anaphylaxis do not increase highly individual gliadin absorption in healthy volunteers

Katharina Anne Scherf, Ann-Christin Lindenau, Luzia Valentini et al. · Clinical and Translational Allergy · 2019 · 38 citations · Full text

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Theresa Ruf, Rafaela Kramer, Andrea Forschner et al. · European Journal of Cancer · 2024 · 38 citations · Full text